Please login to the form below

Not currently logged in
Email:
Password:

ProStrakan takeover moves a step closer

Japanese conglomerate Kyowa Hakko Kirin has bought one share in ProStrakan, taking it a step closer to completing a takeover

Kyowa Hakko Kirin (KHK), the Japanese conglomerate, has bought one share in the Scottish specialist pharmaceuticals company ProStrakan, taking it a step closer to completing a takeover.

Tokyo-based KHK is aiming to buy ProStrakan in a bid to grow its oncology drug business outside of Japan. However, under takeover rules, it must own at least one share to complete the "scheme of arrangement" and transfer the ownership of the company.

ProStrakan, which has its headquarters in Galashiels and employs about 70 of its 300 staff in Scotland, has a number of drugs in key global markets including Sancuso, a novel skin patch for the prevention of chemotherapy-induced nausea and vomiting, and cancer pain treatment Abstral (fentanyl). 

ProStrakan's board has supported KHK's £292m approach unanimously.

31st March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

04 A Healthy Ambience
Creating a Lifeline to the New Digital User...
03 Health Services
How Pharma Companies Can Survive the Patent Cliff Through Digital Innovation...
From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...

Infographics